Uniqure (NASDAQ:QURE) Receives New Coverage from Analysts at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Uniqure (NASDAQ:QURE) in a research note released on Friday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $79.00 target price on the biotechnology company’s stock.

QURE has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an overweight rating and set a $94.00 target price (up from $81.00) on shares of Uniqure in a research report on Monday, July 8th. BidaskClub raised Uniqure from a strong sell rating to a sell rating in a research report on Saturday, October 5th. Chardan Capital reaffirmed a buy rating on shares of Uniqure in a research report on Tuesday, September 3rd. Sanford C. Bernstein started coverage on Uniqure in a research report on Tuesday, September 24th. They set an outperform rating and a $73.00 target price for the company. Finally, Mizuho started coverage on Uniqure in a research report on Thursday, September 12th. They set a buy rating and a $67.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $74.43.

Shares of QURE stock traded up $0.77 on Friday, reaching $42.91. 364,956 shares of the company’s stock were exchanged, compared to its average volume of 572,026. Uniqure has a 52 week low of $21.98 and a 52 week high of $82.49. The company has a current ratio of 8.07, a quick ratio of 8.07 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $1.56 billion, a PE ratio of -18.34 and a beta of 0.84. The company’s fifty day simple moving average is $46.81 and its 200 day simple moving average is $59.70.

Uniqure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, July 29th. The biotechnology company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.08). Uniqure had a negative return on equity of 61.67% and a negative net margin of 1,232.30%. The business had revenue of $2.47 million for the quarter, compared to the consensus estimate of $1.53 million. As a group, sell-side analysts predict that Uniqure will post -3.22 earnings per share for the current fiscal year.

In other news, CEO Matthew C. Kapusta sold 8,000 shares of Uniqure stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $71.45, for a total value of $571,600.00. Following the transaction, the chief executive officer now directly owns 404,839 shares in the company, valued at approximately $28,925,746.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert Gut sold 4,769 shares of Uniqure stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $47.16, for a total value of $224,906.04. Following the completion of the transaction, the insider now owns 35,378 shares in the company, valued at $1,668,426.48. The disclosure for this sale can be found here. Insiders sold a total of 39,229 shares of company stock worth $2,204,241 over the last quarter. Company insiders own 2.91% of the company’s stock.

Large investors have recently made changes to their positions in the company. OMERS ADMINISTRATION Corp purchased a new position in shares of Uniqure in the 2nd quarter valued at $618,000. FMR LLC grew its stake in Uniqure by 0.8% during the 1st quarter. FMR LLC now owns 3,688,791 shares of the biotechnology company’s stock worth $220,036,000 after buying an additional 29,629 shares during the last quarter. Aperio Group LLC purchased a new position in Uniqure during the 2nd quarter worth $83,000. Botty Investors LLC purchased a new position in Uniqure during the 2nd quarter worth $78,000. Finally, Senator Investment Group LP purchased a new position in Uniqure during the 2nd quarter worth $37,121,000. Institutional investors and hedge funds own 69.89% of the company’s stock.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Recommended Story: What is the yield curve?

Analyst Recommendations for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.